RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write a project proposal abstract for 'Safety Mechanisms for Artificial General Intelligence (AGI)' to be submitted under Horizon Europe.

assistant: **Abstract**

Artificial General Intelligence (AGI) represents AI systems with human-level cognitive abilities, capable of understanding, learning, and applying knowledge across a wide range of tasks and domains. While AGI holds immense potential to revolutionize industries, its imminent arrival also poses significant threats to society. Without proper safety mechanisms, AGI could cause unintended harm, be misused by malicious actors, or act autonomously in unpredictable and dangerous ways.Our ambitious goal is to pioneer AGI safety by introducing a new paradigm grounded in cybersecurity principles. Current safety mechanisms—such as safeguards and alignment training—are proactive, serve only as the first line of defense, and are insufficient for the complex, autonomous nature of AGI. Stronger, more explicit mechanisms are essential to handle AGI use cases and mitigate their inherent risks.The new paradigm employs a layered approach: beyond proactive safety, we propose adding two additional protective layers. These layers form the novel domains of active and reactive safety, both built upon a foundation of adversarial robustness. Active safety mechanisms, such as fail safes, enable us to detect and correct harmful thoughts made by the AGI in real time and explicitly, ensuring continuous and safe operation while enabling us to perform auditing when necessary. Reactive safety mechanisms, such as kill switches, serve as a last line of defense to contain or neutralize an AGI when all other measures fail. We also propose research into making these safety mechanisms immutable, preventing adversarial bypass.Our preliminary data shows that these mechanisms are feasible and have high potential to outperform existing AI safety approaches. By fundamentally rethinking AI safety for the AGI era, t
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Horizon 2020 proposal on 'Meeting 100Gbps Ethernet Requirements with CMOS Integrated Circuit Chipset to Dramatically Cut Energy Use in Data Centres'.

assistant: **Innovation**

Data centres are critical modern infrastructure, yet their energy consumption is growing unsustainably. Globally, data centres consume 3% of electricity (higher than the UK’s total consumption) and account for 2% of total greenhouse gas emissions. That gives them the same carbon footprint as the airline industry.Although various energy efficiency gains are being made, the state of the art for data transmission within the data centre is inefficient. Optical Transceiver Modules (OTM), at 40Gbps and above, use power-hungry SiGe/BiCMOS technology in their Integrated Circuits. With a typical, large data centre containing at least 800,000 OTMs, they are responsible for around 8% of total energy use.HiLight Semiconductor Ltd, a “Fabless Chip Company”, has developed MERCURY, an innovative Integrated Circuit chipset, pioneering the use of industry-standard CMOS technology to drive 100Gbps OTMs. With the use of standard CMOS, on 12"" wafers, we are able to produce our Chipset for significantly less than our competitors' BiCMOS on 8"" wafers. Together with our low power innovation, we expect to displace BiCMOS technology entirely over the next few years, just as has been seen previously, at lower datarates.Meeting all industry standards, MERCURY achieves 100Gbps with less than half (57%) the power consumption of BiCMOS solutions. Based on European data centres' energy use and our expected global sales rates, by 2022, MERCURY will save 1.5 Billion kWh every year in Europe and 6 Billion kWh/year globally, helping meet the EC Code of Conduct for Energy Efficiency in Data Centres.This innovation project is designed to undertake vital prototyping, validation and demonstration activities to bring MERCURY to market-readiness. Within five years (2022), we expect to secure 30% of the globa
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Horizon 2020 proposal for the project 'Augmenting and broadening T-cell responses to glioblastoma - therapeutic vaccine platform based on HCMV expressing NKG2D ligands'.

assistant: **Objectives**

The development of an effective vaccine against human cancers is of tremendous importance. Glioblastoma multiforme (GBM) is the most malignant form of brain tumor with extremely poor survival. The human cytomegalovirus (HCMV) is involved in GBM pathogenesis suggesting that viral proteins might provide therapeutic targets. We propose a vaccination strategy against GBM based on a genetically modified HCMV that could target HCMV, as well as tumor specific antigens. The proposal builds on the successful implementation of the ERC-AdG StAdvInn, which investigates a murine cytomegalovirus (MCMV) expressing the NKG2D ligand RAE-1γ (RAE-1γMCMV), which has tremendous potential for strengthening the CD8 T cell response to a vectored antigen (Trsan et al, PNAS 2013). We have shown the strong potential of such vector to act as a CD8 T cell-based vaccine against malignant tumors (Trsan et al, Eur J Immunol 2017). Moreover, the efficiency of this vector can be enhanced by blocking immune checkpoints. We have constructed HCMV expressing the human NKG2D ligand ULBP2 (HCMV/ULBP2) and confirmed its efficacy in vitro and in humanized mice (Tomic et al, PLoS Pathog 2016). Here we propose to determine the capacity of the HCMV/ULBP2 vector in the immune control of GBM. In short, immune cells from GBM patients will be transferred to NSG mice that will be grafted with GBM from the same patients. Mice will be vaccinated with HCMV/ULBP2 vector expressing GBM associated neoantigens. Based on results with the RAE-1γMCMV in the melanoma model and with HCMV/ULBP2 in NSG humanized mice, we expect a strong effector CD8 T cell response to be generated in these mice resulting in the control of tumor in the NSG host. The proposed project activities include: development and validity testing of the prototyp
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Seventh Framework proposal on 'Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility'.

assistant: **Innovation**

NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented and provided evidence of efficacy of carriers and ligands. Over 5 years, NanoAthero will integrate GMP production, the initiation of clinical investigations in high-risk patients, including the preparation of regulatory dossiers, risk and ethical assessments, and the evaluation of the performance of optimized diagnostic and therapeutic compounds. NanoAthero offers a unique opportunity for combining in-depth knowledge of nanocarrier bioengineering and production with state-of the art expertise in imaging and treatment of cardiovascular patients providing a full bench-to-bedside framework within one collaborative consortium of 16 partners from academia, a European association, SMEs and a large pharmaceutical company. NanoAthero gathers together leading chemists, engineers, pharmacists, biologists, toxicologists, clinicians, analysts, ethicists and key-opinion leaders in the field of cardiovascular medicine and early drug development.In NanoAthero, the nanocarriers carrying compounds to visualize thrombus or vulnerable plaques, or to deliver therapeutic agents should be suitable for proof-of-concept in patients. Phase I clinical trials targeting pivotal pathways in atherothrombosis will be performed with nanosystems for diagnosis and treatment of carotid atheroma. NanoAthero aims to propose nanosystems for thrombus imaging, stroke treatment and plaque stabilization in high-risk p
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write a project proposal abstract for 'Control of gene expression and silencing in transgenic plants' to be submitted under Fourth Framework.

assistant: **Abstract**

This proposal, which was initiated by the eight members of a HCM-funded network on gene silencing, combines fourteen European laboratories to elucidate the mechanisms of gene silencing in plants. The aims of the project are to control the expression of recombinant constructs in transgenic plants and to employ silencing as a new approach for controlled gene repression. The project comprises three major objectives: 1. To identify the structural and context- specific requirements for stable expression of transgenes. 2. To understand and exploit silencing of endogenous genes after introduction of transgenic homologues. 3. To define environmental and physiological conditions that favour stable transgene activity. All of the partner laboratories involved in the proposal, represent experts for individual aspects of gene silencing research, with the appropriate research facilities and technical expertise. However, it is highly unlikely that the objectives of this proposal can be accomplished by the work of individual laboratories, which was the reason to initiate a trans-national and interdisciplinary research programme. Experiences from the HCM-network have demonstrated the importance of regular contacts among the participants, as these have helped to identify common silencing mechanisms for the different experimental systems. Due to the feedback gained from public presentation of the network activities, new partner labs have been identified that complement that research approaches. Based on these experiences, the participants of this proposal have defined three major tasks for this proposal: 1. The combination of several expert laboratories to address specific aspects of the objectives mentioned above. 2. The establishment of a management structure that allow a continuous and
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an impact statement for 'Quantifying the structure-function of the neurovascular interface: from micro-circuits to large-scale functional organization', explaining its relevance to EU policy priorities under Horizon 2020.

assistant: **Impact**

Neuronal computations in the brain require a high metabolic budget yet the brain has extremely limited resources; calling for an on-demand, robust supply system to deliver nutrients to active regions. In most cases, neuronal activity results in an increase in blood flow to the active area, a phenomenon called functional hyperaemia. This coupling between neuronal and vascular activtuy underpins the mechanism enabling fMRI to map neuronal activity based on vascular dynamics; further, malfunction of the cellular players involved in coupling is now considered to play a key role in otherwise classically defined neurodegenerative diseases. We lack a concise description of the inner workings of this mechanism and a thorough quantitative description of the neuro-gila-vascular interface; issues that are best addressed by an investigation into the cellular mechanisms, the temporal dynamics and multi-scale spatial organization governing neurovascular coupling. My long-term goal is to provide a unified theory to encapsulate our knowledge on neurovascular coupling. Here, I hypothesize that functional hyperaemia results from the constant integration of vasoactive cues with region-dependent coupling emerging from different neuro-glia-vascular microcircuits, nuances in afferent wiring into vascular contractile elements and/or neuronal activity patterns. I will test this hypothesis with a multi-faceted correlative approach combining: two-photon awake imaging of cellular and vascular dynamics to obtain physiological data unaffected by anaesthetics; super-resolution structural imaging of intact volumes to map the fine details of micro-circuit structure; array-tomography to map in situ the neurovascular signalling machinery and novel optogenic tools to manipulate several of its specific co
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'A novel drug candidate for the treatment of Eosinophilic Esophagitis - an innovative solution for a significant unmet medical need' demonstrating excellence, impact and implementation quality for a Horizon 2020 call.

assistant: **Abstract**

Thelial Technologies, S.A. is a revenue generating drug discovery company that applies its unique, proprietary fly embryo-based technology to find new candidate compounds for the treatment of diseases that can be addressed by cell polarity modulation. By modulating cell polarity it is possible to specifically target a series of indications, where reduced integrity of epithelial cellular barriers is a key to pathologies. Using Thelial’s patented discovery platform theLiTETM the company has identified 28 candidate compounds, of which one – theEoE has been prioritized for further development based on toxicology, efficacy, bioavailability, IP and manufacturing decision points. theEoE will be the first approved product for treatment of Eosinophilic Esophagitis (EoE). EoE is an inflammatory disease of the esophagus elicited by foods and possibly environmental allergens. It occurs when a type of white blood cells, eosinophils, accumulate in the esophagus and persists, causing local injury and inflammation.  Currently, there are no specific cure for the EoE, causing patients’ reduced wellbeing due to uncontrolled and persistent symptoms (e.g. high difficulty in swallowing, pain, nausea, regurgitation, and vomiting). Thelial offers a targeted topical treatment that reduces the clinical symptoms, modifies disease progression through tissue remodeling, and increases the duration of treatment response. These features will allow physicians, patients and payers to benefit from a revolutionary new treatment with fewer side-effects, and lower risk of health complications thanks to a better management of the disease over time. By promoting a first in line targeted therapy for EoE, Thelial’s innovation project perfectly fits the “Europe2020 challenges – for a healthier EU” 1) spending sm
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an executive summary for the EU project 'EASY workflow integration for GENe therapy' (EASYGEN) targeting Horizon Europe.

assistant: **Abstract**

More than 20 million new patients world-wide are diagnosed with cancer every year, and prediction for 2050 foresee over 35 million cancer cases, reflecting the population ageing and growth with a tremendous burden on the health care system. A global WHO survey with 115 participating countries has shown, that only 39% can cover basic cancer care management, financed as core health service. This reveals significant global inequities between high GNP and low- and middle-income countries, which is also reflected in country-specific cancer patient outcomes. Hence, there is a strong need for emerging technologies, that democratize access to cancer treatment, reduce the disparities in cancer care, and significantly reduce the burden on the healthcare workforce. Chimeric Antigen Receptor T-cells are considered as cutting-edge treatment for cancer, but currently only for hematologic malignancies. And although the efficacy is very promising the number of European patients having access to CAR-T treatment is still very limited due to high costs and complex manufacturing and logistic processes. The public private partnerhsip EASYGEN will develop an automated, modular point-of-care cell- and gene-therapy platform, that will allow for the first time hospital on-site CAR-T manufacturing. Designed as a closed, modular, one-stop solution, the device aims to reduce manufacturing time significantly to less than 24 hours and treatment costs by 50%. In a user-centric, co-creation approach, the device will be holistically integrated in a standard hospital workflow, hence empowering healthcare systems to provide CAR-T treatment in any standard hospital setting, capable of conducting leukapheresis. Its modular set-up will ensure adaptability to different ATMPs including solid tumours. Therewit
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe how 'Simulation and Control of Renewable COmbustion (SCIROCCO)' will create measurable scientific, societal and economic impact aligned with Horizon 2020.

assistant: **Impact**

Most renewable energies can only be delivered intermittently. Without massive long-term storage capacities they will never provide 65 % of our energy mix by 2050, as required to limit global warming to 2°. Throughout this period and beyond, energy generation from combustion will remain a key component of this mix. SCIROCCO has two goals: (1) provide effective storage for renewable energies and (2) significantly improve existing combustion systems.  Objective (1) is addressed by extending ‘Power to Gas (PtG)’ strategies, where excess electricity from renewable sources is converted into fuel, usually hydrogen (H2), which is easy to store over long periods and burn when power is needed. Objective (2) is addressed by burning the ‘renewable’ H2 in smart combustors with higher efficiencies and reduced emissions. Today, H2 is diluted in methane lines ('drop-in' strategy) to burn in existing devices. This strategy ignores the exceptional properties of H2, which burns and ignites faster than all other fuels. We will exploit these properties in new chambers that (1) burn H2 within a wide range of fossil fuel mixes and (2) use H2 as a powerful actuator to increase performance. Rather than diluting H2 in other fuels, we will inject H2 into the chamber separately. Research is needed to analyse the structure of these new dual-fuel flames that burn a fossil fuel and H2 simultaneously. This is a challenge for combustion science, requiring a re-think of chamber design and control. These fundamental issues will be addressed for two applications with fundamental societal impact: (1) laminar gas-burning flames (stoves, heaters) and (2) swirled liquid fuel turbulent flames (aerospace and power gas turbines). All cases will be studied experimentally (at IMFT) and numerically (with CERFACS si
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Fifth Framework proposal for the project 'Development of an accurate mites counting and extraction machine ; a monitoring and testing device for the agricultural sector.'.

assistant: **Objectives**

Mite (the Netherlands) and Impacts (Portugal), two biotech companies, propose to develop a mite extraction and counting machine. The R&D partners are the University of Amsterdam and machine developerSchachtner (Germany). Mile faunas are used: (1) for ecotoxicological tests on new types of plant protection products (pesticides). These tests are mandatory before new plant protection products are allowed on the European market. (2) In agriculture to indicate whether to use pesticides for crop protection. This equipment automates the manual counting and extraction of miles enabling accurate and more simplified testing. The increased accuracy will lower the level iron statistically significant mile detection from 40% to a 25% reduction in non-targeted mite faunas. This would comply with European Community directives, as opposed to the existing manual techniques. More accurate testing techniques will reduce the use of pesticides in agriculture, leading to a cleaner environment. The project fits in Theme 1 of the Fifth Framework: 'Quality of Life and Management of Living Resources' The project specifically complies with Key Action 5 'Sustainable Agriculture' (plant health).